<DOC>
	<DOC>NCT01725802</DOC>
	<brief_summary>In this Phase I/IIa study, the effect of continuous subcutaneous administration of LD/CD solution (ND0612) on the safety and PK profile of LD will be examined.</brief_summary>
	<brief_title>A Phase I/IIa Study of Safety, Tolerability and Plasma Concentration of Subcutaneous Continuously-delivered Levodopa/Carbidopa Solution (ND0612) in PD Patients</brief_title>
	<detailed_description>Design: single center, double-blind, randomized, placebo-controlled, crossover study. Study Drug: Subcutaneous (SC), ND0612 (LD/CD solution) or placebo (saline) to be administered via a continuously via the CRONO Five SC pump. A 1-week washout period will apply between the treatments. Population: Eight (8) PD subjects.</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Main Men and women with idiopathic Parkinson's disease Subjects must experience motor fluctuations associated with LD/CD dosing Modified Hoehn and Yahr stage &lt; 5 Subjects must be taking optimized and stable levodopa/dopa decarboxylase inhibitor therapy Women must be postmenopausal, surgically sterilized, or using adequate birth control. Women of childbearing potential must have a negative pregnancy test (serum betaHCG) at screening. Subjects must be age 30 or older. Subjects must be willing and able to give informed consent. Main Subjects with a clinically significant or unstable medical or surgical condition Subjects with clinically significant psychiatric illness. Premenopausal women, not using birth control method. Subjects who have taken experimental medications within 60 days prior to baseline. Subject who have undergone a neurosurgical intervention for Parkinson's disease (e.g., pallidotomy, thalamotomy, transplantation and deep brain stimulation).</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>